Introduction
Endocrine therapy is one of the mainstream treatments of breast cancer, and 5 years of adjuvant tamoxifen has long been considered the standard treatment for early-stage estrogen receptor (ER)-positive breast cancer and significantly reduces ER-positive breast cancer recurrence and mortality throughout the first 10 and 15 years, respectively.
1,2 However, the optimal duration and treatment strategies involving adjuvant endocrine therapy in early breast cancer remain controversial. 3, 4 ER-positive tumors initially have low recurrence rates and a constant and unrelenting risk of relapse that extends up to 15 years. Fisher et al showed that continuous adjuvant tamoxifen treatment for 10 years vs 5 years led to adverse outcomes, and that an extension of endocrine therapy for an additional 5 years is likely to lead to an increase in side effects. 6 Generally, tamoxifen is well tolerated, with the most reported events being hot flushes, osteoporosis, arthralgia and gynecologic symptoms such as vaginal bleeding and discharge. 7 More severe toxicities are venous thromboembolisms, endometrial carcinomas and mood change or depression. 10, 11 For aromatase inhibitors (AIs), hypertension, dyslipidemia, arthralgia and osteoporosis are more frequently described and gynecologic symptoms and hot flushes are less common. 7, 12 Thus, the additional benefits of extending the endocrine therapy need to be appropriately balanced against the risk of side effects.
Furthermore, ER-positive breast cancer is a biologically heterogeneous disease as different biologic types may respond differently to the endocrine treatment. 13, 14 Clinical management of patients should be individualized, with the patient being a key factor in decision making. Currently, the subpopulation of patients who will actually benefit from extended therapy remains unclear, leaving clinicians and patients with uncertainty about whether to continue endocrine therapy. Consequently, we conducted this study to identify the proportion of patients at a substantial risk of late recurrence after 5-year adjuvant endocrine therapy, who might benefit from extended endocrine therapy.
Patients and methods

Patient selection
A total of 1,056 female patients with primary breast cancer who underwent curative resection at the Shanghai General Hospital (Shanghai, People's Republic of China) between January 2006 and December 2011 were reviewed. The inclusion criteria were as follows: 1) positive ER immunohistochemical (IHC) results; 2) stage I-III infiltrating breast carcinoma and 3) completion of 5-year adjuvant endocrine therapy (tamoxifen or AIs). The exclusion criteria were: 1) no endocrine therapy or endocrine therapy ,5 years; 2) metastasis or recurrence, died or lost to follow-up before completion of 5-year endocrine therapy; 3) endocrine therapy .5 years; 4) neoadjuvant therapies before primary surgery and 5) tamoxifen switch to AIs or AIs switch to tamoxifen. Eventually, 327 eligible patients were enrolled in this study (Figure 1 ). The study was approved by the Ethics Committee of Shanghai General Hospital. All patients provided written informed consent for storage and use of their medical information in the hospital database for research purposes.
ihc and pathologic evaluation IHC staining of ER, progesterone receptor (PR), HER2 and Ki-67 was routinely carried out by using Bench Mark GX system (Hoffman-La Roche Ltd., Basel, Switzerland) and was performed on 4 μm slices of formalin-fixed, Tissue sections were stained with hematoxylin and eosin. Histologic grade was evaluated according to the Nottingham grading system. 16 Tumor grade consisted of three microscopic parameters: tubular formation, nuclear pleomorphism and mitotic counts. A score from 1 to 3 was assigned to each component, and the overall score was calculated to determine the histologic grade. A score of 3-5 points was recorded as grade 1, well differentiated; 5-6 points as grade 2, moderately differentiated; and 8-9 points as grade 3, poorly differentiated. All histologic and IHC tumor slides were evaluated by experienced pathologists and examined by senior pathologists.
Follow-up and survival end points
The follow-up was primarily through telephone or data tracking of outpatient or hospital medical records. The contents of follow-up included survival situation, recurrence or no recurrence, adjuvant therapy, imaging examination and tumor marker levels. Latest follow-up was at the end of December 2016, with a median time of 8.5 years (5.6-10.9 years). The end point was recurrence-free survival (RFS) period, defined as the length of time from the date of diagnosis to any invasive breast cancer relapse (including locoregional or distant metastasis), or death, whichever occurred first or was censored at the date of last follow-up. Distant metastasis-free survival (DMFS) was also analyzed in this study.
statistical analysis
Statistical analyses was performed using SPSS 20.0 software. Estimation of RFS and DMFS probability was performed using the Kaplan-Meier log-rank test. Univariate and multivariate analyses were performed using the Cox proportional hazards regression model to identify prognostic factors (including age, menopausal status, tumor size, pathologic type, histologic grade, node status, Ki-67, HER2, PR, TNM stage, endocrine therapy, chemotherapy and radiation therapy), and the variables were included in multivariate analysis when they were found to be statistically significant in univariate analysis. P-values ,0.05 were considered significant.
Results
Patients and characteristics
A total of 327 patients with stage I-III invasive breast cancer were enrolled. All cases did not have distant metastasis and neoadjuvant therapy before surgery. The clinicopathologic characteristics of the study subjects are summarized in Table 1 . A total of 141 (43.1%) patients were ,50 years, and 129 (39.4%) patients were premenopausal. The tumors mainly consisted of invasive ductal carcinomas (82.6%). Subdivisions based on the Ki-67 index were as follows: low proliferation 159 (48.6%) and high proliferation 168 (51.4%), with a cutoff of 14%. PR was expressed in 84.4% of all cases, and 26.3% of the cases were HER2 positive. A total of 20 (6.1%) patients died from breast cancer, 34 (10.4%) patients developed a regional recurrence, and 42 (12.8%) patients suffered from distant relapse. Treatment decision for every grade, lymph node metastasis and high Ki-67 index were significantly associated with worse RFS (P=0.000, 0.003 and 0.008, respectively; Figure 2 ; Table 1 ) and DMFS (P=0.000, 0.002 and 0.032, respectively; Figure 3 ; Table 1 ).
risk factors for recurrence
Risk factors that could potentially influence RFS were evaluated in univariate analyses for each of the 13 variables. Among these variables, five were found to be associated with a significant increase in the risk of locoregional recurrence and distant metastasis, including high histologic grade, lymph node metastasis, Ki-67 index, TNM stage and radiotherapy ( 
risk factors for distant metastasis
Risk factors that could potentially influence DMFS were evaluated in univariate analyses for each of the 13 variables. Among these variables, five were found to be associated with a significant increase in the risk of distant metastasis, including high histologic grade, lymph node metastasis, Ki-67 index, TNM stage and radiotherapy (Table 2) . However, only histologic grade 3 (HR=2.212, 95% CI=1.166-4.194; P=0.015) was significantly associated with increased risk of distant metastasis after elimination of all nonsignificant variables in the multivariate model (Table 3) .
Discussion
Recently, Davies et al reported that continuing tamoxifen for 10 years rather than stopping at 5 years produced an absolute recurrence reduction of 3.7% and a mortality reduction of 2.8%, most notably seen in the second decade after diagnosis. 2 However, the extra benefit in terms of reduced recurrences and death shown in the study was modest, and therefore, it is appropriate to consider that not all patients with early breast cancer require extended endocrine therapy. 
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late recurrence after 5-year adjuvant endocrine therapy the best possible outcomes. 3, 7 Thus, it is critical to identify target populations with substantial risk of late recurrence to implement extended endocrine therapy, such that this therapy is cost-effective. 4 The American Society of Clinical Oncology guideline recommended that women with hormone receptor-positive breast cancer who are pre-or perimenopausal should receive tamoxifen for an initial duration of 5 years, after which extended endocrine therapy is judged by menopausal status. 3 The St Gallen consensus recommended that an extended endocrine therapy for a total of 10 years should be considered for premenopausal women with node-positive or with adverse pathology. 17 This study newly found that patients with more than three positive nodes or grade 3 disease had substantial risk of recurrence, independent of endocrinotherapy regimens (tamoxifen or AIs), which is somewhat a complement of previous studies and suggests that patients with more than three positive nodes or grade 3 disease might require extended endocrine therapy. 14, 18, 19 Pan Hongchao et al reported that even after 5 years of endocrine therapy, distant recurrence rates in years 5-20 were around 1% per year in T1N0 and much greater for those with T2N0 or node-positive disease. 20 Our results showed that distant metastasis was still common (12.8%) after 5-year adjuvant treatment and accounted for approximately half (55.3%) of the recurrence, and that histologic grade 3 was the only independent variable that influenced distant metastasis after completion of 5-year adjuvant tamoxifen or AIs, which indicates that these patients might require extended therapy. Several reports showed similar results. 18, 19 The predictive role of biomarkers on extended treatment of breast cancer has been investigated in only a few 15, 21 However, Ki-67 was not found to be an independent predictor of outcome, but high Ki-67 had a significantly higher risk of late recurrence in univariate analyses.
Whether the PR status affects the prognosis of ER-positive breast cancer patients is still controversial. Compared to ER-positive/PR-positive tumors, ER-positive/PR-negative tumors are frequently associated with upregulation of specific oncogenic pathways, including PI3K/Akt/mTOR. 13, 22 However, in this study, PR status was not significantly associated with late RFS or DMFS, which was similar to the results of the BIG 1-98 trial and the ATAC trial. 8, 9 Beyond this, we found that HER2 was also not associated with late recurrence in ER-positive patients, which might be attributed to the small size of patients with a high expression of HER2 (26.3%) and was similar to the results of the ATAC trial and different with the BIG 1-98 trial. 8, 9 In addition to specific clinical and pathologic features, multigene expression signatures are capable of predicting the risk of late recurrence after treatment in patients with ER-positive breast cancer. 18 Currently, only three multiparameter gene expression tests, the PAM50 risk of recurrence, Breast Cancer Index and the Endopredict assay, are shown to be prognostic beyond 5 years and may potentially discriminate patients into low and high risk for late distant recurrence. [23] [24] [25] However, currently, clinicians should not make decisions based on such assays because there is no consensus about how low the annual risk of recurrence should be to avoid extended adjuvant endocrine therapy. 8, 26 Nonetheless, extended endocrine therapy is a promising strategy to further reduce the risk of recurrence. 4, 14 Prospective studies are still needed to confirm the results given above, and emphasis should be laid on refining the evidence to include subpopulations of patients who would benefit most from extended endocrine therapy. By tailoring for individual treatment, overtreatment, side effects and unnecessary costs will be prevented and great value will be gained in the treatment of breast cancer.
Conclusion
Late relapse after completion of 5-year adjuvant endocrine therapy was still common, and grade 3 and more than three positive nodes were the risk factors of late recurrence; however, grade 3 was the only risk factor of late distant metastasis. Our results might be helpful to identify patients with higher risk, who may be candidates for extended endocrine therapy. With the available data, the decision making as regards to extended endocrine treatment should, therefore, focus not only on the cancer biology alone, but also include assessment of individual risk of late recurrence based on patient's clinicopathologic characteristics and available molecular signatures, menopausal status, treatment side effects and patients' preference.
